236 related articles for article (PubMed ID: 22130621)
1. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Bickenbach KA; Gonen M; Tang LH; O'Reilly E; Goodman K; Brennan MF; D'Angelica MI; Dematteo RP; Fong Y; Jarnagin WR; Allen PJ
Ann Surg Oncol; 2012 May; 19(5):1663-9. PubMed ID: 22130621
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
[TBL] [Abstract][Full Text] [Related]
3. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
[TBL] [Abstract][Full Text] [Related]
4. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Rashid OM; Pimiento JM; Gamenthaler AW; Nguyen P; Ha TT; Hutchinson T; Springett G; Hoffe S; Shridhar R; Hodul PJ; Johnson BL; Illig K; Armstrong PA; Centeno BA; Fulp WJ; Chen DT; Malafa MP
Ann Surg Oncol; 2016 Apr; 23(4):1371-9. PubMed ID: 26661409
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.
Sherman WH; Hecht E; Leung D; Chu K
Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734
[TBL] [Abstract][Full Text] [Related]
8. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial.
Snady H; Bruckner H; Cooperman A; Paradiso J; Kiefer L
Cancer; 2000 Jul; 89(2):314-27. PubMed ID: 10918161
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Allendorf JD; Lauerman M; Bill A; DiGiorgi M; Goetz N; Vakiani E; Remotti H; Schrope B; Sherman W; Hall M; Fine RL; Chabot JA
J Gastrointest Surg; 2008 Jan; 12(1):91-100. PubMed ID: 17786524
[TBL] [Abstract][Full Text] [Related]
10. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
You DD; Lee HG; Heo JS; Choi SH; Choi DW
J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.
Turrini O; Viret F; Moureau-Zabotto L; Guiramand J; Moutardier V; Lelong B; Giovannini M; Delpero JR
Eur J Surg Oncol; 2009 Dec; 35(12):1306-11. PubMed ID: 19576722
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
[TBL] [Abstract][Full Text] [Related]
14. Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Kluger MD; Rashid MF; Rosario VL; Schrope BA; Steinman JA; Hecht EM; Chabot JA
J Gastrointest Surg; 2018 Feb; 22(2):235-241. PubMed ID: 28895032
[TBL] [Abstract][Full Text] [Related]
15. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Cunningham SC; Cusnir M; Burdick RK; Van Echo DA; Moesinger R
Clin Adv Hematol Oncol; 2003 Dec; 1(12):741-2; discussion 743. PubMed ID: 16258479
[No Abstract] [Full Text] [Related]
17. Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer.
Kozak GM; Epstein JD; Deshmukh SP; Scott BB; Keith SW; Lavu H; Yeo CJ; Winter JM
J Gastrointest Surg; 2018 Feb; 22(2):288-294. PubMed ID: 29139084
[TBL] [Abstract][Full Text] [Related]
18. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
Varadhachary GR; Wolff RA; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Abdalla E; Wang H; Staerkel GA; Lee JH; Ross WA; Tamm EP; Bhosale PR; Krishnan S; Das P; Ho L; Xiong H; Abbruzzese JL; Evans DB
J Clin Oncol; 2008 Jul; 26(21):3487-95. PubMed ID: 18640929
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
[TBL] [Abstract][Full Text] [Related]
20. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]